Novo Nordisk is rolling out a tablet version of Ozempic (semaglutide) across the United States starting May 4, bringing a well-known injectable treatment into a pill format. It sounds simple—same drug, different delivery—but in reality, getting a peptide-based therapy into an oral form has been a long-standing scientific hurdle, so this is… kind of a big deal. For years, Ozempic has been associated with weekly injections, widely prescribed for adults with Type 2 diabetes not just to control blood sugar but also to reduce the risk of serious cardiovascular events like heart attacks and strokes.